United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for ADIAL PHARMACEUTICALS, INC.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -170.73% | -620.19% | 119.19% | 54.35% | 35.21% | 26.08% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -136.16% | -174.55% | -322.85% | -322.66% | -322.61% | -323.13% |
| Total Assets | $6,673,367.00 | $2,469,931.93 | $2,469,931.93 | $2,469,931.93 | $2,469,931.93 | $2,469,931.93 |
| Sector average | $3,280,499,225.95 | $3,298,345,309.75 | $3,676,894,011.56 | |||
| Net Income | -$7,977,171.00 | -$7,979,637.32 | -$7,974,226.86 | -$7,969,595.45 | -$7,968,242.64 | -$7,981,038.91 |
| $4,262,561,283.40 |
| $4,994,412,918.01 |
| $5,761,557,240.51 |